These results support the notion that PGD2 acts as a mediator of plaque associated inflammation in the AD brain and they could also explain the pharmacologic mechanisms underlying the favorable response of patients with AD to non-steroidal anti-inflammatory drugs (Mohri et al., 2007). The gene discussed is PTGDS; the disease is Alzheimer disease.